Alnylam Pharmaceuticals, Inc.

(NASDAQ:ALNY)

17.89

+0.30 (1.71%)

Dec 04 - Close

Open
17.43
High
18.21
Low
17.43
Vol.
395.24K
Mkt Cap
728.38M
52Wk High
36.37
52Wk Low
16.37
Avg. Vol.
487.50K
P/E (Trailing)
-54.21
Beta
0.99
Short %
16.40%
Div. Yield
—

After-Hours 17.88 -0.01 (-0.06%) Thu, 4 Dec 2008 7:40 PM

Company Profile

Alnylam Pharmaceuticals, Inc.

300 Third Street

Cambridge, MA 02142

United States - Map

Phone: (617) 551-8200

Fax: (617) 551-8101

Website: www.alnylam.com

CEO: Dr. John M. Maraganore, Ph.D.

Employees: 129

Sector: Healthcare

Industry Group: Drugs

Industry: Biotechnology

Develop and commercialize new RNA interface drugs.

A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes.

Recent news for ALNY

Recent opinions on ALNY

No recent Opinions for ALNY

Top members owning ALNY

Members owning ALNY also own

NDAQ (33.33%), NTRS (33.33%), NUVA (33.33%), OTTR (33.33%), AEP (33.33%)

Member sentiment: Neutral